Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lung Neoplasms 1371Carcinoma, Non-Small-Cell Lung 1080Breast Neoplasms 183Neoplasms 145Small Cell Lung Carcinoma 137Colorectal Neoplasms 104Adenocarcinoma of Lung 87Melanoma 84Prostatic Neoplasms 80Pancreatic Neoplasms 79Esophageal Neoplasms 70Head and Neck Neoplasms 69Ovarian Neoplasms 67Colonic Neoplasms 67Stomach Neoplasms 63Urinary Bladder Neoplasms 49Neoplasm Metastasis 49Disease 49Mesothelioma 44Liver Neoplasms 44Pulmonary Disease, Chronic Obstructive 42Mesothelioma, Malignant 42Brain Neoplasms 37Lung Diseases 36Carcinoma, Renal Cell 35Uterine Cervical Neoplasms 34Pleural Effusion, Malignant 34Kidney Neoplasms 33NSCLC 31Carcinoma 28

Interventions

lorlatinib 1ceritinib 1brigatinib 1alectinib 1Crizotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × ALK-positive NSCLC × Thoracic × Clear all
NCT04647110 2023-04-06

Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.

Pfizer

Completed
549 enrolled 28 charts
Thoracic

ALK-positive NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡